MKGAF Stock News 168.0000 05/08/2014 12:16:53 Merck Kgaa Dm 5

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Merck Kgaa Dm 5 (MKGAF) 168.0000 $MKGAF

Merck KGaA Starts Study on Tecemotide - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 5:55PM CDT
Oncothyreon announced that Merck KGaA commenced a phase III study, START2, on oncology candidate, tecemotide (L-BLP25).

Merck KGaA and Auxogyn Collaborate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 4:00PM CDT
Merck KGaA entered into an exclusive license agreement with Auxogyn, Inc. for the Early Embryo Viability Assessment (Eeva) test.

Merck KGaA, Pfizer and Broad Institute Collaborate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 4:10PM CDT
Recently, Merck KGaA's biopharmaceutical division, Merck Serono, entered into a research agreement with Pfizer Inc. and the Broad Institute in Cambridge, MA.

Merck KGaA Enrolls First Patient in Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 1:28PM CDT
Merck KGaA enrolled the first patient in a phase III study (ESPART) on Pergoveris

Merck KGaA Misses 2013 Earnings & Rev Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 9:30AM CST
Merck KGaA reported 2013 earnings per ADR of $11.70, up 19.2% year over year but below the Zacks Consensus Estimate of $11.99.

Avanir Reports Narrower Loss, Revs Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 06, 11:40AM CST
Avanir Pharma reported first quarter fiscal 2014 net loss per share of 7 cents, narrower than the Zacks Consensus Estimate of a loss of 8 cents

Threshold Pharma Completes Enrolment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 31, 3:45PM CST
Threshold Pharma completed enrolling patients in its phase III study, which is being conducted to evaluate TH-302 for the treatment of advanced soft tissue sarcoma.

Avanir Reports Wider Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 11, 8:37AM CST
Avanir reported 4Q13 net loss per share of 10 cents, wider than the Zacks Consensus Estimate of a loss of 7 cents

Threshold Pharma's TH-302 in Melanoma Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 15, 12:00PM CDT
Threshold Pharmaceuticals recently initiated a phase II trial on its pipeline candidate, TH-302.

Update on Threshold Pharma's TH-302 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 08, 10:20PM CDT
Threshold Pharma announced an amendment in the protocol for its pivotal phase III study of TH-302

Sanofi's Lemtrada Gets CHMP Backing - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 01, 11:40AM CDT
The Committee for Medicinal Products for Human Use recommended the approval of Lemtrada

Data on Merck KGaA's L-BLP25 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 22, 9:00PM CDT
Merck KGaA presented detailed results on its oncology candidate L-BLP25, from the phase III study, START.

Merck KGaA Posts Higher Y/Y Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 15, 10:24AM CDT
Merck KGaA reported first quarter 2013 earnings per American Depository Receipt (ADR) of $2.79, up 28.1% year over year.

Merck KGaA-CBRX Renew Agreement - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 11, 3:00PM CDT
Merck KGaA and Columbia Labs renewed a license and supply agreement for Crinone (progesterone gel), extending it for an additional five years

Sanofi Reports Lemtrada Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 27, 4:30PM CDT
Sanofi's subsidiary, Genzyme, announced interim data on Lemtrada.

Merck KGaA-BMY Collaborate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 21, 4:15PM CDT
Merck KGaA announced a deal with Bristol-Myers Squibb for the promotion of different formulations of Glucophage (metformin hydrochloride) in China.

Merck KGaA - Nordic Bioscience Collaborate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 20, 4:00PM CDT
Merck KGaA recently announced a strategic deal with Nordic Bioscience Clinical Development A/S for its pipeline candidate, sprifermin.

Threshold Cuts Loss, Misses Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 13, 9:00AM CDT
Threshold Pharmaceuticals Inc. reported fourth-quarter 2012 net loss per share of 10 cents, narrower than the Zacks Consensus Estimate of a loss of 12 cents.

Strong Quarter for Merck KGaA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 08, 9:40AM CST
Merck KGaA reported fourth quarter 2012 earnings per American Depository Receipt of $2.66, up 18.8% year over year.

Positive Data from BMRN's PKU-016 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 20, 4:50PM CST
BioMarin announced positive results from the PKU-016 ASCEND study.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

N? KOA's 11-Year Journey: From Art to Legacy

Updated Category News Views 51

N? KOA: Leather Meets Polynesian Tattoo Art N? KOA, the Hawaii-based leather goods brand, knows a thing or two about weaving art into tradition. Eleven years back, they took the plunge with a compact line of men's bifold wallets, featuring designs by just three talented Polynesian tattoo artists. Today, that tribe's grown to 16 artists from across the Pacific, each...

Continue Reading
Domino’s Faces Legal Heat: Investors' Eyes On DPZ

Updated Category News Views 56

Domino's Pizza Under the Legal Microscope Picture this, folks: Domino's Pizza (NASDAQ: DPZ) is caught in a legal whirlwind that might give its shareholders a rollercoaster of a read in the coming weeks. On the docket is a serious probe led by Johnson Fistel, a law outfit with quite the reputation for defending shareholder interests. The focus? Whether certain hot shots at...

Continue Reading
Review Insurance Coverage After Major Life Changes

Updated Category News Views 70

Why Life Changes Demand an Insurance Review The nitty-gritty of life doesn't sit still—marriages, babies, job changes, and home deals or steals each bring their own clutter to the table. One thing's for sure: when your life shifts, your insurance ought to keep pace. Insurance Agent Nick Hogan drops the dime in the latest HelloNation article, laying it bare why...

Continue Reading
Rothera's KPI Swap Approval: A Financial Game Changer

Updated Category News Views 162

Revolutionizing Risk Management with KPI Swaps Boy, if there's one thing that gets my ticker going, it's the buzz of innovation in financial markets. Rothera just landed a CFTC stamp of approval for something that's about to shake up how institutional traders manage risk: Key Performance Indicator (KPI) swaps. And can you believe it? This isn't just another derivative...

Continue Reading
West Fraser Tackles Grim Quarter: Indefinite Mill Closures

Updated Category News Views 91

Bracing For Impact: The Tough Truth About West Fraser's Recent Moves Things are looking a bit bleak over at West Fraser Timber Co. They've just dropped their Q3 2026 results, ringing the bell with a hefty $80 million loss. As if that wasn't enough, the company's decided to indefinitely curtail a couple of mills—one in Lanett, Alabama and the other in Leola, Arkansas....

Continue Reading
UPM Defies Market Challenges: Strong Q3 Cash Flow

Updated Category News Views 121

UPM's Impressive Q3 Performance Amidst Challenges UPM-Kymmene Corporation just dropped their Q3 numbers, and let me tell ya, there's a lot to digest. In the face of some pretty gnarly market conditions—think destocking and those pesky cost inflations—they've managed to pull a rabbit out of the hat with strong cash flow. That's not a small feat, folks; it's a damn...

Continue Reading
Aker BP's Q3 2026: Strong Earnings Fuel Optimism

Updated Category News Views 0

Third Quarter Overview: Riding the Wave Aker BP's third quarter report is a raucous symphony of successes that have the market nodding in admiration. Marking significant strides with their offshore projects, the company seems to be in a cavalier mood as it boasts higher sales volumes and promising financials. Net production came in at 374 mboepd, dampened slightly by...

Continue Reading
ESENTIA Lifts EBITDA, Reduces Debt, Eyes Expansion

Updated Category News Views 0

ESENTIA Flexes Financial Muscles: What's the Deal? Walk with me through the gritty world of financials, and you’ll see that ESENTIA’s latest figures are a mixed bag with a tantalizing upside. We're talking about adjusted EBITDA ticking up to a cool $86 million in the third quarter of '26, a 1.3% lift from last year. Not too shabby, eh? Especially when you're grappling...

Continue Reading
Software Updates Costly: UX Not the Biggest Culprit

Updated Category News Views 109

Breaking Updates Trump UX Changes Here's the real scoop: software updates that break functionality are setting companies back more than those user experience (UX) tweaks that folks gripe about but usually muddle through. According to a recent LITSLINK study, even three figures that supposedly quantify UX losses turn out to be questionable at best. Real-world Disasters:...

Continue Reading
Tabañero Spices Up Holidays with $10 Gift Sets

Updated Category News Views 92

Hot Sauce, Spicy Gifting, and Bold Barbecue When holiday cheer mixes with a dash of heat, you end up with something as electrifying as Tabañero's latest offerings. This Florida-based player is nudging its way into the gift-giving scene with a lineup that's as spicy as it is thoughtful. Frankly, if you're scrambling for stocking stuffers or a memorable Secret Santa...

Continue Reading

Top 5 Most Recently Viewed Articles

Lindahl Reed Secures Long-Term Energy Management Contract

Updated Category News Views 244

Lindahl Reed Awarded a Significant Contract Lindahl Reed, a prominent provider of technical, engineering, scientific, and research services, has secured a five-year contract to offer Resource Efficiency Management (REM) Support Services. This award involves strengthening energy resilience and security for vital military facilities. Enhancing Energy Resilience and Security...

Continue Reading
Worksport Sets Ambitious Goals with New Product Launches

Updated Category News Views 53

Worksport's Drive for Revenue Expansion Worksport Ltd. (NASDAQ: WKSP) is making waves in the clean energy sector by introducing new products while also targeting remarkable revenue growth. As the company transitions from generating annual million-dollar revenues to aiming for weekly revenues on a much larger scale, its strategic updates are noteworthy. CEO Steven Rossi is...

Continue Reading
Upcoming Green Bond Auction from Reykjavik Energy

Updated Category News Views 166

Exciting Green Bond Auction by Reykjavik Energy Reykjavik Energy, also known as Orkuveita Reykjavíkur (OR), is gearing up for an important event in the financial landscape with its upcoming green bond auction. This auction is designated to take place on a Tuesday in late April 2025, showcasing a selection of environmentally focused bonds that are becoming increasingly...

Continue Reading
Storable and SafeLease Launch Integration for Enhanced Services

Updated Category News Views 363

Storable and SafeLease Join Forces for Improved Offerings Storable, a leader in technology solutions for the self-storage sector, has exciting news to share. The company has announced a long-term integration agreement with SafeLease, a renowned provider of tenant protection and insurance solutions. This partnership will allow self-storage operators to access SafeLease's...

Continue Reading
ZoomInfo Technologies (ZI) Investor Concerns Grow After Earnings Plunge

Updated Category News Views 85

Investors React to ZoomInfo Technologies' Earnings Disappointment Recently, ZoomInfo Technologies, Inc. (ZI), a software and data solutions provider, has found itself under intense scrutiny from investors following what many are calling a disappointing earnings report. The negative response from the market has escalated into a class action lawsuit against the company and...

Continue Reading